The ELN 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates re-classification and incorporation of new gene mutations in the present model can further improve and individualize prognostication.

Subjects:
Myeloid Neoplasia
This content is only available as a PDF.
Copyright © 2024 American Society of Hematology
2024

Article PDF first page preview

Article PDF first page preview
You do not currently have access to this content.
Sign in via your Institution